



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 106101.145)

TECH CENTER 1600/2900

OCT 12 2001

RECEIVED

In re Application of: Li et al.

Examiner: To Be Assigned

Serial No. 09/817,913

Group Art Unit: 1645

Filing Date: March 26, 2001

For: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF SPECIFIC HISTONE
DEACETYLASE ISOFORMS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date:

10/4/01

Diana Havens
Diana Havens

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached form PTO-1449, copies of which are enclosed. This information disclosure statement is being filed under 37 C.F.R. § 1.97 (b) before the mailing date of the first Office Action, therefore no fee is believed to be due.


This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents do not constitute prior art under United States law, Applicants reserve the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

U.S. Patent Application No. 09/817,913
Page Two

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.

Please charge any fees which might be due in connection with this matter to Deposit Account No. 08-0219. If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,


Robert McIsaac, Ph.D., Reg. No. 46,918
Agent for Applicants

Date: October 9, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



RECEIVED

OCT 12 2001

GAU1645

TECH CENTER 1600/2900
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 106101.145)

In re Application of: Li et al.) Examiner: To Be Assigned
Serial No. 09/817,913) Group Art Unit: 1645
Filing Date: March 26, 2001)

For: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF SPECIFIC HISTONE
DEACETYLASE ISOFORMS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 10/4/01

Diana Havens
Diana Havens

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for filing in the above-identified patent application are the following documents:

1. Information Disclosure Statement (2 pages);
2. Form 1449 (1 page);
3. References as Cited (8);
4. Certificate of First Class Mailing, and;
5. Return Postcard.

U.S.S.N. 09/817,913
Page Two

No fees are believed to be due in connection with this submission. However, please charge any fees which might be due or credit any overpayment to our Deposit Account No. 08-0219.

Respectfully submitted,



Robert McIsaac, Ph.D., Reg. No. 46,918
Agent for Applicants

Date: October 4, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



Subt. For, PTO-1449				Docket Number 106101.145		Application Number 09/817,913	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Li et al.			
				Filing Date 03/26/2001		Group Art Unit 1645	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
A1	Yoshida M et al., "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A" J Biol Chem. 1990 Oct 5;265(28):17174-9.	
A2	Taunton J et al., "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p" Science. 1996 Apr 19;272(5260):408-11.	
A3	Yoshida M et al., "Effects of trichostatins on differentiation of murine erythroleukemia cells" Cancer Res. 1987 Jul 15;47(14):3688-91.	
A4	Sanchez del Pino MM "Properties of the yeast nuclear histone deacetylase" Biochem J. 1994 Nov 1;303 (Pt 3):723-9.	
A5	Hu E et al., "Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor" J Biol Chem. 2000 May 19;275(20):15254-64.	
A6	Kao HY et al., "Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression" Genes Dev. 2000 Jan 1;14(1):55-66.	
A7	Grozinger CM et al., "Three proteins define a class of human histone deacetylases related to yeast Hda1p" Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4868-73.	
A8	Csordas A et al., "On the biological role of histone acetylation" Biochem J. 1990 Jan 1;265(1):23-38	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	